Autogenous brachial-brachial XXXX for vein access. Haemodynamic factors predicting outcome and 1 year clinical data.

@entity1 @entity1009 @entity281 @entity292 @entity850
Two-stage autogenous brachial vein-brachial artery access (ABBA) has been proposed as an option where adequate superficial vein is not available for the creation of conventional haemodialysis fistulae. METHODS: This report depicts the clinical outcome of a series of 17 consecutive @entity1 who underwent ABBA in a single centre. Of the 17 @entity1 , nine had had at least one previous arterioventricular (AV) @entity292 or graft, and eight were new to haemodialysis. Patencies were assessed using the Kaplan-Meier survival analysis. RESULTS: In 14 @entity1 , the brachial vein was transposed (82%) and the time to transposition ranged from 4 to 26 weeks (median time: 6 weeks). The functional patency rate was 45.75% at 12 months. After stage one, all @entity292 that went on to develop well had a brachial vein flow of at least 900 ml @entity1009 ), and this was significantly higher than in @entity292 that failed to develop (p=0.005). The maturation rate in our study was 65% and the median time to cannulation of the @entity292 was 8 weeks from the stage 1. Of the 17 @entity1 , 12 (71%) experienced at least one complication. Ten (59%) demonstrated moderate-to-severe @entity850 ; eight of which necessitated angioplasty and/or percutaneous mechanical thrombolysis. CONCLUSIONS: ABBA was characterised by a high incidence of complications and a long period to achieve maturation. Despite close monitoring and a high rate of secondary interventions, the patency rate was low. With this experience, we now only consider it an alternative in @entity1 without adequate superficial veins, who have had failed grafts or where there is a very high risk of @entity281 .
